With A Fast-Growing Ebola Outbreak Carrying a Crude Fatality Rate Above 48%, NNVC is Moving NV-387 into the Clinic while a Second Potential Application in Resurgent Measles Adds Another Catalyst to the Story

Greetings,

Sometimes a small-cap biotech story gets interesting because of a promising drug candidate. And sometimes the opportunity becomes even more compelling when that candidate is moving toward a clinical trial at the exact moment a major unmet medical need is escalating.

That is the setup developing around NanoViricides, Inc. (NYSE American: NNVC).

NNVC announced September 15 that its Phase II clinical trial of NV-387 Oral Gummies as a treatment for Ebola is scheduled to begin this month in the Democratic Republic of Congo (DRC), targeting the ongoing outbreak of Bundibugyo ebolavirus. 

The timing is significant. According to the World Health Organization, the DRC outbreak had reached 6,757 confirmed cases and 3,267 deaths as of September 7, representing a crude case-fatality ratio of 48.3%. WHO also reported that the outbreak had expanded to 61 health zones across six provinces. 

For NNVC, the upcoming trial represents something investors will want to watch closely: a real-world test of NV-387 against a serious viral disease, while the same drug candidate is simultaneously being developed for additional viral targets — including measles and Mpox!

Phase 2 matters a lot, especially for a small biotech like NNVC, because it means the drug is moving beyond early safety testing and into a stage where researchers are looking more seriously at whether the drug actually works in patients.

NV-387 is Heading into the Clinic

The biggest near-term development for NNVC is unquestionably the planned Ebola trial.

NanoViricides says the first Ebola patient could receive NV-387 Oral Gummies as early as next week, barring logistical impediments caused by the outbreak itself. 

The planned study is an adaptive Phase IIA/IIB trial, beginning with a safety and dose run-in before moving into a randomized, controlled efficacy evaluation. 

That transition from laboratory and animal research into human clinical testing is an important milestone for any biotechnology company.

What makes the story particularly interesting is how NV-387 is administered.

NNVC says NV-387 is currently the only orally administered drug in clinical trials as a treatment for Ebola, to the company's knowledge. Other therapies being studied in the DRC include treatments delivered by infusion. 

In an outbreak occurring across resource-limited areas, the potential advantages of an oral treatment are straightforward: administration could potentially be simpler and more scalable than therapies requiring intravenous delivery.

This is a potentially important clinical catalyst to watch!

A Major Unmet Medical Need

The backdrop to the trial is difficult to ignore.

WHO says the current Bundibugyo virus outbreak has become the largest Ebola outbreak ever reported in the DRC, with sustained transmission and geographic expansion. As of September 7, cases had been reported across 61 health zones, with Ituri remaining the epicenter. 

WHO has also classified the risk within the DRC as very high, while the risk to countries sharing land borders with the DRC remains high. 

Importantly, WHO notes that the Bundibugyo species involved in the current outbreak is one for which there is no specific treatment or vaccine, although potential interventions are being studied. 

That creates an unusually relevant environment for an antiviral candidate entering a clinical trial.

For NNVC, the question is no longer simply whether NV-387 can demonstrate activity in preclinical models. The next question is whether that activity can translate into meaningful results in human Ebola patients.

That is the catalyst to have on radar.

Why NV387 is Different

At the heart of the NNVC story is the company's nanoviricide technology.

NanoViricides describes NV-387 as a broad-spectrum antiviral designed around a host-mimetic approach. Rather than relying solely on targeting a highly variable viral feature, the company's technology is designed to mimic features on host cells that viruses use during infection. 

The company believes this approach could make it more difficult for viruses to escape through mutation.

NNVC also points to prior animal-model work in which oral NV-387 outperformed intravenous remdesivir in extending survival in a lethal coronavirus infection model. The company believes this provides additional support for advancing the drug into human testing against Ebola. 

The upcoming Ebola trial will provide a much more important test!

Measles is Another Potential Catalyst

While Ebola is the immediate catalyst, measles could give the NV-387 story another major dimension.

NNVC announced in August that it is preparing for a Phase II clinical trial program evaluating NV-387 as a treatment for measles. 

The company cited 2,903 confirmed measles cases in the United States as of August 27, 2026, compared with 2,289 confirmed cases during all of 2025. 

The company also highlighted significant measles activity internationally, including an expanding outbreak in Bangladesh.

And there is a particularly interesting regulatory angle here.

The FDA has granted NV-387 both Orphan Drug Designation and Rare Pediatric Disease Drug Designation for measles, according to NanoViricides. 

The Rare Pediatric Disease designation can make the company eligible for a Priority Review Voucher if the drug ultimately receives marketing approval for the qualifying indication and all applicable requirements are satisfied. 

A Priority Review Voucher can potentially have significant commercial value because it can be used to obtain priority review for another qualifying drug application or, subject to applicable rules, potentially transferred.

NNVC itself notes that a PRV would only become available if the required conditions are met following successful development and approval.

Multiple Viral Targets

One of the more intriguing aspects of NNVC is that it isn't building its story around a single disease.

The company identifies NV-387 as its lead broad-spectrum antiviral candidate and is developing it across multiple potential applications, including Ebola, Mpox, measles, RSV, influenza and coronavirus-related infections. 

The company is also developing NV-HHV-1 for shingles.

That gives investors multiple potential clinical and regulatory catalysts to follow rather than a single binary event.

The Ebola program, however, stands out because it is now approaching human testing against an active outbreak where the medical need is substantial.

In Summary

NanoViricides is entering an important phase of its development.

The company has a broad-spectrum antiviral candidate moving toward a Phase II clinical trial for Ebola in the DRC, right as the Bundibugyo outbreak continues to expand. WHO's latest available data show thousands of confirmed cases and deaths, with a crude fatality ratio above 48%. 

At the same time, the company is preparing a clinical development program for measles, another viral disease experiencing renewed outbreaks globally. 

NV-387 has already received FDA Rare Pediatric Disease Drug Designation for measles, creating the possibility of a future Priority Review Voucher if the drug ultimately meets the applicable requirements for approval. 

The upcoming Ebola trial is an important event for NNVC.

NNVC is a name worth putting on the radar now because NV-387 is moving from potential to clinical testing, with Ebola as the immediate catalyst and measles providing another potentially important avenue for development.

The next chapter could begin with the first patient dosed in the Ebola trial!